Mocetinostat (MGCD0103)

For research use only.

Catalog No.S1122 Synonyms: MG0103

65 publications

Mocetinostat (MGCD0103) Chemical Structure

Molecular Weight(MW): 396.44

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Mocetinostat (MGCD0103) has been cited by 65 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy0PEBp NWnlc|E5UUN3ME2zMlA1KM7:TR?= NYjsc5VkOjZ|N{iwN|g>
BT549 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQUWg1QCCq NWLQcWNtUUN3ME20MlM5KM7:TR?= NWHnWItpOjZ|N{iwN|g>
MCF7 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HmS|Q5KGh? NGT1OZdKSzVyPUCuOlch|ryP MX6yOlM4QDB|OB?=
T47D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrIOFghcA>? MUDJR|UxRTFwMUeg{txO M4flO|I3Ozd6MEO4
MOLP8 NX30NoY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37GNFQ5KGh? MY\JR|UxRTBwNtMxJFAvODUQvF2= M1XOTlI3ODlzNUG4
Panc1 M{f2S2Z2dmO2aX;uJGF{e2G7 MlPINE42NzFxMj61JO69VQ>? MVK0PEBp NFrCTHJFVVOR NVnoVGZtfXC{ZXf1cIF1\XNibXnSMVIxOw>? MWOyOVg4Ojl2MR?=
Panc1 NVfIXVVkTnWwY4Tpc44hSXO|YYm= Ml\3NE42NzFxMj61JO69VQ>? M1;WNFQ5KGh? MlPjSG1UVw>? NIfDeopz\WS3Y3XzJIV5eHKnc4Ppc44hd2ZiWlXCNUBwdiCkb4ToJI1TVkFiYX7kJJBzd3SnaX6gcIV3\W{EoB?= MViyOVg4Ojl2MR?=
Panc1 MYrBdI9xfG:|aYOgRZN{[Xl? M2rKeVHDqM7:TR?= NUGzN5BpPzMEoHi= NGjQ[2RFVVOR MWLz[Y5{cXSrenXzJHBidmNzIHPlcIx{KG[xcjDn[Y1kcXSjYnnu[U1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mnq4NlU5PzJ7NEG=
Panc1 MofTR4VtdCCYaXHibYxqfHliQYPzZZk> MoPMNeKh|ryP NF\6[lA4OsLiaB?= MortSG1UVw>? MYDlcohidmOnczDn[Y1kcXSjYnnu[U1qdmS3Y3XzJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn M1r6ZlI2QDd{OUSx
MMCs MWDGeY5kfGmxbjDBd5NigQ>? MXKxJO69dQ>? M2TMWFAuPDhiaB?= M3HUNYlv[3KnYYPld{BPWFKDIIDyc5RmcW5iZYjwdoV{e2mxbtMgNk446oDVMz61JIZwdGR? NGW2c2QzPDR3MUO3PC=>
MMCs NGHaO4hHfW6ldHnvckBCe3OjeR?= MWKwMlUwOSEQvF2= NXKzNYFUOjRiaB?= NEfOWop{cG:5czC0OU1nd2ymIIP0bY12dGG2aX;uJIlvKGOJTWCgcIV3\Wy| NX61Oo1VOjR2NUGzO|g>
MMCs M3\0emZ2dmO2aX;uJGF{e2G7 NX\JcY56OcLizszN M37ocFI1KGh? MXnpcoNz\WG|ZYOgTGFVKGGldHn2bZR6 MnH2NlQ1PTF|N{i=
MMCs MXTGeY5kfGmxbjDBd5NigQ>? M{\LflHDqM7:TR?= NYm5Oo53OjRiaB?= MnPzZZVodWWwdIOg[4xw[mGuIHHj[ZR6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGg{NUt7L{G0JEhJOy2NOT:xOIFkMSCjbnSgTFQuUzF{IDjIOE1MOTKjYzm= MV2yOFQ2OTN5OB?=
MMCs NEO4VI5HfW6ldHnvckBCe3OjeR?= M3rOW|HDqM7:TR?= NUjzbJk6Pi1{NDDo MUnkc5NmNWSncHXu[IVvfGy7IHnubIljcXS|IITo[UB1emmvZYTofYxifGmxbjDs[ZZmdCCxZjDIN{1MQSBqSEOtT|lu\TNr NHnU[2UzPDR3MUO3PC=>
BxPC-3 M2HIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS5cWk6TUN3ME2xMlEh|ryP NVzNd4g1OjF|N{W2O|k>
AsPC-1 NUHIU4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILYRVRGSzVyPUOuPUDPxE1? NE[3OmkzOTN5NU[3PS=>
MiaPaca-2 NGnXW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7YSWM2OD1yLk[g{txO MmD2NlE{PzV4N{m=
Panc-1 NX3vTYxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDFR|UxRTFwODFOwG0> NE[4RpIzOTN5NU[3PS=>
PAXF 546L† MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO3PYV6TUN3ME2xMlUh|ryP NEPWb|UzOTN5NU[3PS=>
PAXF 1657L† M{TCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjCd5h1TUN3ME2wMlMh|ryP M1qzfVIyOzd3Nke5
HCT15 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTDPYtKSzVyPUCuO{DPxE1? MlvCNlE{OTd2NUW=
HT-29 NXHoPWZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyTWM2OD1yLkeg{txO NXzyR3VEOjF|MUe0OVU>
SW48 NWLlc5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SzSWlEPTB;MD64JO69VQ>? NUDoU3ZbOjF|MUe0OVU>
SW620 M1XDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFizszN MkS4NlE{OTd2NUW=
HMEC NWTudJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHyTWM2OD1zOTFOwG0> NWnlc3dNOjF|MUe0OVU>
ANBL6  MXnGeY5kfGmxbjDBd5NigQ>? M4DIZ|HDqM7:TR?= MVeyOEBp Moqy[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO|aX;u Mm\2NlEyPzF6MkG=
LP1 MXXGeY5kfGmxbjDBd5NigQ>? MmmzNeKh|ryP M36yVlI1KGh? M{LrSIVvcGGwY3XzJFUuSUNvaX7keYNm\CCPQVfFMWE{KGenbnWg[ZhxemW|c3nvci=> NVXQV|BJOjFzN{G4NlE>
HD-LM2 NWLp[2U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXvdmk4OsLiaB?= MoqzSG1UVw>? NGf5fpBKSzVyPUGuPFgh|ryP NGrXUlYzODh6MEGwOy=>
L428 M17GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NuKhcA>? M17FbmROW09? NVvMdJp5UUN3ME2xMlk3KM7:TR?= MViyNFg5ODFyNx?=
KM-H2 NUPQRmhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3NuKhcA>? NGLubJZFVVOR M4\2RWlEPTB;Mj64OkDPxE1? MlXENlA5QDBzMEe=
HD-LM2 NIjFVZdHfW6ldHnvckBCe3OjeR?= M13tPVAvOS1{IN88US=> M13pSlI1KGkEoB?= MWDEUXNQ NIfP[25{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx NGnZbXAzODh6MEGwOy=>
L428 MUXGeY5kfGmxbjDBd5NigQ>? NEXPc3cxNjFvMjFOwG0> MmH4NlQhcMLi NUjGN296TE2VTx?= NY\SZ5A1e2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=> M2jue|IxQDhyMUC3
KM-H2 NUn1SZFWTnWwY4Tpc44hSXO|YYm= M2DDfVAvOS1{IN88US=> NVL3R496OjRiaNMg MXTEUXNQ MYHzbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz NFGwVoozODh6MEGwOy=>
HD-LM2 NYXtW|VjSXCxcITvd4l{KEG|c3H5 NFL6VncxNjFxMD61M|Eh|ryP M1XtflQ5KGh? NFvR[pNFVVOR NHnz[3dqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 Mn71NlA5QDBzMEe=
L428 NVz3TGx1SXCxcITvd4l{KEG|c3H5 MmrpNE4yNzBwNT:xJO69VQ>? MYK0PEBp NXLPPW5MTE2VTx?= NELIZ4JqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MoLENlA5QDBzMEe=
KM-H2 MmHpRZBweHSxc3nzJGF{e2G7 NV7z[phrOC5zL{CuOU8yKM7:TR?= M37MWFQ5KGh? NHHoOXJFVVOR MVXpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MVWyNFg5ODFyNx?=
HD-LM2 M1vXeWZ2dmO2aX;uJGF{e2G7 NXHvR4w6OcLizszN MorlNlQwPDhiaB?= NYnhSGUyTE2VTx?= MVXkc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz MmnCNlA5QDBzMEe=
L428 Mme3SpVv[3Srb36gRZN{[Xl? NWjJdWY6OcLizszN MljJNlQwPDhiaB?= Mn\iSG1UVw>? MlS4[I94dnKnZ4XsZZRmeyC[SVHQMEBi[3SrdnH0[YQh[2G|cHHz[ZMhQSCjbnSgNy=> M2fwNlIxQDhyMUC3
KM-H2 NVntU2czTnWwY4Tpc44hSXO|YYm= M17HRVHDqM7:TR?= MnjZNlQwPDhiaB?= MUPEUXNQ M1;nWIRwf26{ZXf1cIF1\XNiWFnBVEwh[WO2aY\heIVlKGOjc4Dhd4V{KDliYX7kJFM> Mk\pNlA5QDBzMEe=
HD-LM2 M{CzWmZ2dmO2aX;uJGF{e2G7 NF3aWZIxNjVxMTFOwG0> NXXSSVI3OjRxNEigbC=> MWPEUXNQ M{Dvb5VxemWpdXzheIV{KFSQRj5OtUBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MV2yNFg5ODFyNx?=
L428 MmrrSpVv[3Srb36gRZN{[Xl? M{n2elAvPS9zIN88US=> MkHENlQwPDhiaB?= NYToTIRSTE2VTx?= MlTXeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NFjETpYzODh6MEGwOy=>
KM-H2 MYfGeY5kfGmxbjDBd5NigQ>? MUiwMlUwOSEQvF2= NIfiOYgzPC92ODDo MlH2SG1UVw>? MnvOeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NXfs[mwzOjB6OECxNFc>
HD-LM2 NEnj[mZHfW6ldHnvckBCe3OjeR?= MV[xxsDPxE1? M37KVVAvOjVvNEigbC=> NF:3[XBFVVOR MYDhZ5RqfmG2ZYOgUmYuc0J? NF31XogzODh6MEGwOy=>
L428 NHK3ZlhHfW6ldHnvckBCe3OjeR?= MX[xxsDPxE1? MkL2NE4zPS12ODDo NHjvd4JFVVOR NGHOd2di[3SrdnH0[ZMhVkZva1K= MkLENlA5QDBzMEe=
KM-H2 NID5c4lHfW6ldHnvckBCe3OjeR?= MmjKNeKh|ryP MUKwMlI2NTR6IHi= MYrEUXNQ NGPuUY5i[3SrdnH0[ZMhVkZva1K= MkHWNlA5QDBzMEe=
H526 M1vxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTGTI0yUUN3ME20PFAhdk1? NUCzV3MyOjB4OEK2OFM>
H146 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInoT5JKSzVyPUO1JI5O NWnyN4lHOjB4OEK2OFM>
H82 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXscYtKSzVyPUK1NEBvVQ>? Ml7UNlA3QDJ4NEO=
DMS114 NX7vUZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZ2MDDuUS=> NXrxe|N5OjB4OEK2OFM>
HeLa NG\2b3dHfW6ldHnvckBCe3OjeR?= NYPUOlNJOC5|LUGwJO69VQ>? MoDuPEBp NWLWRnpXTE2VTx?= MXvpcoNz\WG|ZYOgZYNmfHmuYYTl[EBJOyCNOTCoTFNMQUGlKTDheEAyOCEQvF2= NETS[WkzODV|OEi0NC=>
HeLa MmHKSpVv[3Srb36gRZN{[Xl? MonvNE4{NTFyIN88US=> M1rYRVghcA>? NHvTbFJFVVOR MX\pcoNz\WG|ZYOgZ4F{eGG|ZTCzJIFv\CB5IHHjeIl3[XSrb36g[I9{\SCmZYDlcoRmdnSueR?= NHrCVmkzODV|OEi0NC=>
HeLa MmK0SpVv[3Srb36gRZN{[Xl? NVntOYpNOTBizszNxsA> NFvnNpY3NzF{L{K0JIg> MnztSG1UVw>? NWC3eGtLcW6mdXPld{BucXSxdHnjJIFk[3WvdXzheIlwdiCjbnSg[IVt[XmnZDDwNlEh\XiycnXzd4lwdg>? MWiyNFU{QDh2MB?=
HeLa  M1\hNGZ2dmO2aX;uJGF{e2G7 M2m5NVExKM7:TdMg NUn2WWJxPyCq NIDYcGZFVVOR NEPsU|VlcXO{dYD0d{Bvd3KvYXygd5BqdmSuZTDjbIVkc3CxaX70JIZ2dmO2aX;u MYmyNFU{QDh2MB?=
PBMC  NVzvSmxESXCxcITvd4l{KEG|c3H5 Ml3oNE42NzJxMzFOwG0> MkDlNlQwPDhiaB?= M3\CbIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NWTabG1{OjB2ME[5OFc>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-H3 / Ac-H4 / Ac-tubulin ; 

PubMed: 29186204     


Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.

Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; 

PubMed: 27551526     


(a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. 

29186204 27551526
Immunofluorescence
Nanog / MHC ; 

PubMed: 26240433     


c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.

E-cadherin / ZEB1 ; 

PubMed: 25872941     


Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.

26240433 25872941
Growth inhibition assay
Cell viability; 

PubMed: 26378038     


B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software. 

26378038
In vivo MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. [1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. [2]

Protocol

Kinase Assay:[1]
- Collapse

HDAC enzyme assay in vitro:

The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:[1]
- Collapse
  • Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
  • Concentrations: 0-60 μM
  • Incubation Time: 72 hours
  • Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO2. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing H1437 tumors
  • Dosages: 80 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.44
Formula

C23H20N6O

CAS No. 726169-73-9
Storage powder
in solvent
Synonyms MG0103
Smiles NC1=CC=CC=C1NC(=O)C2=CC=C(CNC3=NC=CC(=N3)C4=CC=CN=C4)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04299113 Not yet recruiting Drug: Vinorelbine|Drug: Mocetinostat Rhabdomyosarcoma Jonsson Comprehensive Cancer Center|Mirati Therapeutics Inc.|Phase One Foundation June 1 2020 Phase 1
NCT02993991 Withdrawn Drug: Mocetinostat|Biological: Durvalumab Squamous Cell Carcinoma Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network Toronto|Mirati Therapeutics Inc.|AstraZeneca October 10 2017 Phase 1
NCT02805660 Active not recruiting Drug: mocetinostat|Drug: durvalumab Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02236195 Completed Drug: Mocetinostat Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2
NCT00666497 Terminated Drug: Azacitidine|Drug: MGCD0103 Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) Mirati Therapeutics Inc. June 2008 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Mocetinostat|Mocetinostat ic50|Mocetinostat price|Mocetinostat cost|Mocetinostat solubility dmso|Mocetinostat purchase|Mocetinostat manufacturer|Mocetinostat research buy|Mocetinostat order|Mocetinostat mouse|Mocetinostat chemical structure|Mocetinostat mw|Mocetinostat molecular weight|Mocetinostat datasheet|Mocetinostat supplier|Mocetinostat in vitro|Mocetinostat cell line|Mocetinostat concentration|Mocetinostat nmr|Mocetinostat in vivo|Mocetinostat clinical trial|Mocetinostat inhibitor|Mocetinostat Epigenetics inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID